Maziar Mike Doustdar
New CEO Doustdar is tasked with executing a reset at Novo Nordisk, streamlining its slow culture after significant market share loss and a 60% stock price correction.
Sources say the 33-year veteran is a "decisive, crisis-tested operator" whose world-class commercial skillset is a strong match for orchestrating Novo's restructuring.
However, his suitability is challenged by a "particularly lacking" direct operational experience in the US, Novo Nordisk's most important market and a key source of concern.
By submitting this form, you are agreeing to ManagementTrack’s Privacy Policy. You can choose to opt out of marketing or advertising emails using the ‘unsubscibe’ link included in our emails.
The best
The best
The best
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.